OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/28/2025
Back to search
Official data from USPTO
CLINIGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
02/28/2025
Trademark type
Word
Nice classes
5
Filing date
10/20/2022
Registration date
05/07/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/07/2024
Last transaction
02/28/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
16
Owner location
GB
Examiner
JOHNSON, AISHA
Law office
L10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Clinigen Healthcare Limited
Representatives
Venner Shipley LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the preventiontreatment and adjunctive therapy of cancer; anti-cancer preparations; pharmaceutical preparations for treating herpes viruses; anticholinergic pharmaceutical preparations
Publications
History of USPTO decisions and trademark events.
28 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/12/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/12/2025
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
12/07/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/31/2024
FIMP
FINAL DISPOSITION PROCESSED
10/31/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/07/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/07/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/26/2024
PUBO
PUBLISHED FOR OPPOSITION
02/20/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/07/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/07/2024
NPUB
NOTICE OF PUBLICATION
01/31/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/16/2024
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/30/2023
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
10/30/2023
RFNT
REFUSAL PROCESSED BY IB
09/17/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
09/16/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/29/2023
RFRR
REFUSAL PROCESSED BY MPU
08/29/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/09/2023
CNRT
NON-FINAL ACTION WRITTEN
08/08/2023
DOCK
ASSIGNED TO EXAMINER
08/04/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
02/10/2023
MAFR
APPLICATION FILING RECEIPT MAILED
12/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/28/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
11/25/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
11/17/2022
Continuous trademark protection
Get notified about every new filing that threatens CLINIGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.